Hot Topics: Transitions of Care
|
|
- Amos Parsons
- 6 years ago
- Views:
Transcription
1 Our quarterly newsletter is a great way to stay up-to-date on emerging clinical information, medication safety issues, and Larkin s Hospital medication policies and procedures. Hot Topics: Transitions of Care Importance of Transitions of care The Joint Commission developed the National Patient Safety standards for hospitals discussing the safely use of medications and the importance of effective communication among providers as a priority. An area that has the potential for medication errors is when patients move from one health care provider or setting to another. Medication errors increase mortality rates, length of hospital stays, and readmission. The Center for Medicare and Medicaid Services (CMS) enacted strategies to reduce readmissions and limit unnecessary cost. CMS will not fully reimburse for a related diagnosis, such as myocardial infarction, chronic heart failure, or pneumonia, if readmission occurs within 30 day of a discharge from the same or another hospital. By reducing readmission rates, hospitals have a significant impact on improving patient care. One approach for reducing readmission rates is to improve the transitions of care from hospitals to other healthcare settings. Transition of care includes different type of services and settings designed to promote the safe and transfer of patients between levels of health care and other care settings. It plays an important role in elderly patients with multiple chronic conditions and complex therapeutic regimens. Elderly patients receive care from many providers and move more often within health care settings. Therefore, poor communication among healthcare providers, incomplete transfer of information, and inadequate education to patients may improve the providing quality of care of our patents. An effective transfer requires well-timed, accurate, and sufficient communication of between healthcare providers, so the next healthcare provider assumes responsibility for patient care. Transition can improve outcomes and patient satisfaction, decrease cost, and ensure that patients understand ways to seek help when needed. The FDA has deemed the drug shortage problem a national crisis. The following medications are drug shortages at Larkin Community Hospital: Cefepime (Maxipime) Shortage: 1gm and 2gm Option: Ensure appropriate use and consider alternatives when possible Editor: Marlene Calix Director: Ana Bendeck, RPh Clinical pharmacist: Teresita Martin, PharmD Luis Marquez, RPh Indhira Acosta, PharmD Estela Trimino, PharmD, BCPS Pharmacy resident: Marlene Calix Page 1 of 5
2 Clinical Corner Summary of the Clinical Practical Guidelines for Anticoagulation (AC) Conversion among parenteral anticoagulation From/To Enoxaparin Fondaparinux Stop heparin and start LMWH at the time the next dose of heparin would be given Stop heparin and start at the time the next dose of heparin would be given within 2 hours after discontinuation of heparin Enoxaparin (Lovenox) Initiate heparin when next enoxaparin dose is Initiate parenteral AC when next enoxaparin dose is when next enoxaparin dose is Fondaparinux (Arixtra) Stop fondaparinux and give the first the dose of heparin at the same time the next dose of fondaparinux would have been given Stop fondaparinux and give first dose of LMWH at the time the next dose of fondaparinux would have been given when next fondaparinux dose is No hepatic failure: Start heparin within 2 Hepatic insufficiency: Start heparin within 2-4 Start LMWH within 2 Hepatic insufficiency: Start LMWH within 2-4 Start fondaparinux within 2 hours of stopping Hepatic insufficiency: Start fondaparinux within 2-4 hours of stopping Conversion from parenteral to oral anticoagulation for the treatment of VTE From/To Warfarin Dabigatran Apixaban or Rivaroxaban Overlap heparin with warfarin for at least 5 days and until INR is in therapeutics range for 24 hours Discontinue heparin infusion and initiate dabigatran 2 hours later Initiate Apixaban or Rivaroxaban within 2 hours after discontinuation of heparin Enoxaparin (Lovenox) Overlap therapeutic enoxaparin dose with warfarin for at least 5 days and until INR is >2.0 for 24 hours Discontinue LMWH and administer dabigatran 0-2 hours before the next administration of LMWH Initiate Apixaban or Rivaroxaban when next enoxaparin dose expected to be given Fondaparinux (Arixtra) Overlap Fondaparinux with warfarin for at least 5 days and until INR is >2.0 for 24 hours Start Fondaparinux alone and after a minimum of 5 days, stop Fondaparinux. Give first dose of dabigatran or Initiate Apixaban or rivaroxaban when next Fondaparinux dose is Page 2 of 5
3 Conversion among the oral anticoagulation From/To Warfarin Dabigatran Apixaban Rivaroxaban Warfarin (Coumadin) dabigatran when INR <2 when INR <2 rivaroxaban when INR <2 (Manufacture when INR <3) Dabigatran (Pradaxa) CrCl>50ml/min: start warfarin 3 and stop dabigatran 3 days later CrCl >30ml/min, wait 12 dabigatran to initiate CrCl >30ml/min, wait 12 rivaroxaban to initiate CrCl 30-50ml/min: start warfarin and stop dabigatran 2 days later CrCl 15-30ml/min: start warfarin and stop dabigatran 1 day later CrCl<30ml/min, wait 24 dabigatran to initiate CrCl<30ml/min, wait 24 rivaroxaban to initiate CrCl<15ml/min: not recommended Apixaban (Eliquis) Rivaroxaban (Xarelto) Discontinue and begin a parenteral anticoagulant and warfarin at the time the next dose of is due; discontinue the parenteral anticoagulant when INR reaches an acceptable range Discontinue rivaroxaban and initiate both a parenteral anticoagulant and warfarin at the time the next dose of rivaroxaban would have been taken Discontinue and begin taking the new non-warfarin usual time of the next schedule dose of Discontinue rivaroxaban and initiate the time that the next rivaroxaban dose would have been taken Discontinue rivaroxaban and initiate the time that the next rivaroxaban dose would have been taken Discontinue and begin taking the new non-warfarin usual time of the next schedule dose of Page 3 of 5
4 Pre/Post-surgery anticoagulation Anticoagulant/ Antiplatelet Before procedure Re-start of therapy Reversal agent Warfarin (Coumadin) Dabigatran (Pradaxa) Rivaroxaban (Xarelto) Apixaban (Eliquis) Enoxaparin (Lovenox) Stop warfarin therapy approximately 5 days before surgery CrCl >50ml/min Hold 1-2 days before procedure CrCl 30-50ml/min hold 2 days before surgery CrCl <30 hold for 2-5 days Hold at least 24 hours before procedure Hold at least 48 hours for elective surgery or invasive procedures with moderate - high risk high of bleeding Hold at least 24 hours for invasive procedures with low risk of bleeding Hold dose at least 24hours prior to surgery Restart after 12 to 24hours after surgery in conjunction with low dose heparin or LMWH if necessary His bleeding risk surgery: Vitamin K Praxbind Protamine sulfate Fondaparinux (Arixtra) Hold dose 6 hours before surgery Stop Fondaparinux approximately hours Consider a shorter acting agent until the patient is tolerant to anticoagulation Protamine sulfate P&T Updates Recommendations for the substitution of Procainamide Procainamide forms part of the malignant crash cart. This medication is use as an option for irregular tachycardia caused by preexisted atrial fibrillation when electric cardioversion is ineffective or unfeasible, or atrial fibrillation returns. However, procainamide is unavailable in the hospital and for that reason other antiarrhythmic therapy should be considered as an options amiodarone, sotalol, and lidocaine. Therefore, procainamide was removed from the malignant crash cart and was replaced with amiodarone. Page 4 of 5
5 FDA MedWatch Safety Alerts The FDA communicates important new safety information gained through their medication reporting system, MedWatch or via MedWatch safety alerts. Clinicians are urged to report any adverse drug events through MedWatch. The following are some recent safety alerts: FDA drug safety communication: FDA warns about serious risk and death when combining opioid pain or coughs medicines with benzodiazepines; require its strongest warning The FDA is warning healthcare providers of the use of opioid pain medicines with benzodiazepines due to the cause of serious side effects, including difficult breathing and deaths. Opioids are used to treat pain and cough; as for benzodiazepines are used to treat anxiety, insomnia, and seizures. As a result, the FDA is adding a Boxed Warning, the strongest warning, to the drug labeling or prescription of opioid pain and prescription of opioid cough medicines, and benzodiazepines. The FDA recommends for healthcare providers to limit the use of opioid medicines with benzodiazepines or other CNS depressants. The use of opioids and benzo s should be limited to patients for whom alternative treatment options are not available. If these medications are prescribed concurrently then the dosage and duration of each drug should be minimize as much as possible. Testosterone and other anabolic androgenic steroids: FDA statement-risk associated with abuse and dependence The FDA made changes for all prescription testosterone products and added a new warning stating the abuse and dependence of androgenic steroids. Abuse of testosterone may lead to serious safety risks affecting the heart, brain, liver, mental health, and endocrine system. Individuals abusing high doses of testosterone have reported withdrawal symptoms, such as depression, fatigue, irritability, loss of appetite, decreased libido, and insomnia. The new warning will alert prescribers about the abuse of testosterone produces and about the serious adverse events. The FDA recommends patients and prescriber or reporting adverse events or side effects related with the use of testosterone products. Medication Safety Fluoroquinolones are associated with disabling and possible permanent adverse effects of the tendons, muscles, nerves, and central nervous system. For that reason, the FDA recommends for fluoroquinolones reserved as the last option for patients with acute bacterial sinusitis, acute bacterial bronchitis, or uncomplicated urinary tract infection due to the risk of these major adverse events. The FDA evaluated post-marketing reports of adverse events associated with fluoroquinolones to reevaluate the relative risk and benefits in treating these infections. The FDA was able to identify 178 cases in which healthy patients had taken oral fluoroquinolones to treat these conditions and developed disabling irreversible side effects. The average duration of these effects was 14 months and up to 9 years. Three out of four cases occurred in patient s ages years. The most common side effects that were seeing in the trials were tendinitis and tendon rupture, muscle pain or weakness, joint pain, peripheral neuropathy, and central nervous systems effects. The longest side effect that was reported in almost all cases was pain associated with the musculoskeletal adverse reaction. Therefore, fluoroquinolones should be avoided in patients who have experience serious adverse reactions. However, for serious infections the benefits outweigh the risks and it would be appropriate to maintain these antibiotics as a therapeutic option. Page 5 of 5
Change from lovenox to pradaxa
P ford residence southampton, ny Change from lovenox to pradaxa 14-11-2017 We wanted to put out a friendly reminder that the Ask 3 Teach 3 (A3T3) initiative is indeed full swing. This is an multidisciplinary
More informationAppendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS
Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationAnticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017
Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationNEWSLETTER DUE CARE PROGRAM. WINTER 2014 Summer 2015 COMMONLY ASKED QUESTION:
DUE CARE PROGRAM NEWSLETTER WINTER 2014 Summer 2015 Lisa Sather, RPh DUR Coordinator Mountain-Pacific Quality Health 3404 Cooney Drive Helena, MT 59602 406-457-5818 The DUE CARE PROGRAM, administered by
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationReducing the Use of Reversal Agents in a Community Hospital
4//0 Objectives Reducing the Use of Reversal Agents in a Community Hospital Maria Paulina Duarte, PharmD PGY- Pharmacy Resident Mercy Hospital, A Campus of Plantation General Hospital Review the appropriate
More informationPost-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.
Medication Time to wait after last dose Post-procedure dose ok after hours Can pull catheter hours after last dose Can give next dose hours after pulling catheter Enoxaparin (Lovenox) Prophylactic dose
More informationADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL
Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationto a DOAC anticoagulants (DOACs) dosing of DOACs for various indications switching from a DOAC and switching
Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services } Identify the FDA approved direct oral anticoagulants (DOACs) } Distinguish the differences in the dosing of DOACs for various indications
More informationLovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto
Lovenox to xarelto The Borg System is 100 % Lovenox to xarelto Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationQUEST FOR THE IDEAL ANTICOAGULANT: A PATIENT-CENTERED APPROACH TO TREATMENT
QUEST FOR THE IDEAL ANTICOAGULANT: A PATIENT-CENTERED APPROACH TO TREATMENT SATURDAY/11:30AM-12:30PM ACPE UAN: 0107-9999-17-237-L01-T 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for
More informationManagement of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules
Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Jane Vo, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationAntiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center
Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade
More informationUW MEDICINE PATIENT EDUCATION. Treating Blood Clots. What is a blood clot? DRAFT
UW MEDICINE PATIENT EDUCATION Treating Blood Clots About deep vein thrombosis (DVT) and pulmonary embolism (PE) and how they are treated This handout explains blood clots, their symptoms, and how they
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationTSHP 2014 Annual Seminar 1
Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationWarfarin 2016: New State of the Art for an Old Drug
Warfarin 2016: New State of the Art for an Old Drug Dan Witt, PharmD Professor (Clinical) and Vice Chair, Department of Pharmacotherapy, Assistant Dean for Clinical Affairs, University of Utah College
More informationI. UNIFORM FORMULARY REVIEW PROCESS
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code 1074g, as implemented
More informationPreventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE
Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE What Is Atrial Fibrillation? Atrial fibrillation also called AFib or AF is the most common abnormal heart rhythm, affecting an
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationMEDICATION MANAGEMENT IN VTE FROM CONVENTIONAL TO NEW
MEDICATION MANAGEMENT IN VTE FROM CONVENTIONAL TO NEW Presented by: David B. Coriale RPh. Pharm D BCPS Clinical Pharmacy Manger Oneida Healthcare Oneida, NY WWW.HEALTHUNITS.COM Presentation John is a
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationAnticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationa. A pharmacist may order a baseline SCr per protocol
UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin
More informationWelcome to the New England QIN-QIO Medication Safety Webinar!
Welcome to the New England QIN-QIO Medication Safety Webinar! Thank you for joining. Our presentation will begin shortly. If you haven t already, please dial in to the audio line: 888-895-6448 Passcode:
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationManaging Perioperative Anticoagulation. Edie Shen MD
Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationPharmacy Prep. Qualifying Pharmacy Review
Pharmacy Prep 2014 Misbah Biabani, Ph.D Director, Tips Review Centres 5460 Yonge St. Suites 209 & 210 Toronto ON M2N 6K7, Canada Luay Petros, R.Ph Pharmacy Manager, Wal-Mart, Canada 1 Disclaimer Your use
More informationClinical Policy: Dabigatran (Pradaxa) Reference Number: CP.PMN.49 Effective Date: Last Review Date: 05.18
Clinical Policy: (Pradaxa) Reference Number: CP.PMN.49 Effective Date: 05.01.12 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationHeparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital
Heparin-Induced Thrombocytopenia Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital Heparin-induced thrombocytopenia (HIT) A serious concern associated with thrombosis development following
More informationAcetaminophen interaction with eliquis
Acetaminophen interaction with eliquis Acetaminophen Oral on WebMD safety, interactions, pictures, warnings and user ratings. 23-2-2018 View drug interactions between acetaminophen and Eliquis. These medicines
More informationAtrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.
Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More informationEmergent Anticoagulation Reversal
U N C M E D I C A L C E N T E R G U I D E L I N E Emergent Anticoagulation Reversal I. PURPOSE: The purpose of these instructions is to provide guidelines for the reversal of or management of bleeding
More informationGuidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients
More informationTreatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society
Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society Coumadin (Warfarin) Does this medication need ongoing monitoring of blood clotting times? Yes.
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationPHARMACY AND THERAPEUTICS NEWSLETTER
Apr 2015 ` Volume 22 Number 1 In This Issue... Changes to Formulary 1 Comparison of Oral Anticoagulant Agents 2 PDTM 2015 Distribution 3 Pediatric and Neonatal Drug Dosing in PDTM 3 Health Canada MedEffect
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationNovel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology
Novel Anticoagulant Drugs by: Dr. M. Kamandi Fellowship of hematology and Oncology A-Novel Oral Anticoagulants A drug that is: safe and effective has predictable pharmacology has few drug drug and drug
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationReversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationAntibiotic Utilization in SNF/LTC Role of Consultant Pharmacist
Antibiotic Utilization in SNF/LTC Role of Consultant Pharmacist Hennie Garza, M.S.Pharm, R.Ph., C.D.E. Director of Pharmacy Senior Care Centers Dallas, TX Potential Roles for Consultant Pharmacists Provide/help
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationThyroid or Parathyroid Surgery
PATIENT EDUCATION patienteducation.osumc.edu This handout gives you information about what to expect before, during and after your surgery. If you have questions, ask your nurse or doctor for more information.
More informationEAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY
EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY K.A.O. Tikkinen (Chair), R. Cartwright, M.K. Gould, R. Naspro, G. Novara, P.M. Sandset, P.D. Violette, G.H. Guyatt Introduction Utilising recent
More informationNorth East Essex Medicines Management Committee
Colchester Hospital University NHS Foundation Trust North East Essex Clinical Commissioning Group North East Essex Medicines Management Committee ORAL ANTICOAGULANT (Vit K antagonist only) MANAGEMENT GUIDELINES
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAbbreviated Class Update: Anticoagulants, oral and parenteral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationG02.2A Transport Office of the Medical Director TRANSPORT TO THE COMPREHENSIVE STROKE CENTER (HSC) Implementation date October 30, 2018
G02.2A Transport Office of the Medical Director Basic 2018-10-04 TRANSPORT TO THE COMPREHENSIVE STROKE CENTER (HSC) Implementation date October 30, 2018 17 years & older Primary Intermediate Advanced Critical
More informationIndividualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationA Year in Review: Novel Drug Approvals and Important FDA Safety Communications for the Year 2016
A Year in Review: Novel Drug Approvals and Important FDA Safety Communications for the Year 2016 Steven F. Nerenberg, Pharm.D. Clinical Assistant Professor Emergency Medicine Pharmacist Rutgers, The State
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More information4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients
4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients Assess Thrombosis risk: baseline risk in an individual patient plus additional thrombotic risk
More informationGlobal Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017
Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021) April 2017 Global Anticoagulants Market Scope of the Report The report entitled Global Anticoagulants Market: Size, Trends & Forecasts
More informationUnder Triage and Anticoagulants in the Geriatric Trauma Population Fragile Must be Italian. Barry McKenzie, MD St. Vincent Healthcare
Under Triage and Anticoagulants in the Geriatric Trauma Population Fragile Must be Italian Barry McKenzie, MD St. Vincent Healthcare Objectives Describe the increasing frequency of trauma patients being
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationGuideline for Treatment of Head Injury in the Anticoagulated Patient
Guideline for Treatment of Head Injury in the Anticoagulated Patient GUIDELINE: GUIDELINE FOR TREATMENT OF HEAD INJURY IN THE ANTICOAGULATED PATIENT BACKGROUND: Chronic anticoagulation therapy is used
More informationSupplementary Online Content
Supplementary Online Content Caldeira D, Canastro M, Barra M, et al. Risk of substantial intraocular bleeding with novel oral anticoagulants: systematic review and meta-analysis. JAMA Ophthalmol. Published
More informationTim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss
More information1/21/2016 UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE OBJECTIVES AGING GOALS BEERS CRITERIA
UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE I have no financial conflict of interest to disclose. Lacey Charbonneau, Pharm.D. PGY-1 Community Practice Resident Baptist Medical
More information